# A Study of ZEN003694 in People With Squamous Cell Lung Cancer

Source: https://onco.cc/trials/nct05607108/  
OnCo record `nct05607108` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ZEN-3694 in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.

## Summary

A Study of ZEN003694 in People With Squamous Cell Lung Cancer is a phase 2, interventional study registered as NCT05607108 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 13 participants, started 2022-11-01 and due to reach its primary completion in 2027-11. Interventions recorded: ZEN003694. Conditions listed: Squamous Cell Lung Cancer. Primary outcome: overall response rate (ORR). Lung eligibility wording from the registry: "* Histologically-confirmed squamous cell lung cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05607108
- Phase: 2
- Setting: Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 13

## Sources

- ClinicalTrials.gov NCT05607108: https://clinicaltrials.gov/study/NCT05607108

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- drugs: [ZEN-3694](https://onco.cc/drugs/zen-3694/)
- companies: [Zenith Epigenetics](https://onco.cc/companies/zenith-epigenetics/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05607108.json